A Comparison of Activated Coagulation Time-Based Techniques for Anticoagulation During Cardiac Surgery With Cardiopulmonary Bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 22, Issue 1, 2008, Pages 47-52

  Slight, Robert D ^a   Buell, Rivan ^a   Nzewi, Onyekwelu C ^a   McClelland, David B L ^b   Mankad, Pankaj S ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

activated coagulation time; blood heparin concentration; cardiopulmonary bypass; coagulation system

Indexed keywords

ENFLURANE; FENTANYL; HEPARIN; MIDAZOLAM; PANCURONIUM; PROPOFOL; PROTAMINE;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYSTALLOID; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; FEMALE; HEART SURGERY; HEMOSTASIS; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBE;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; FEMALE; HEMOSTASIS; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTAMINES; THROMBELASTOGRAPHY; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 38849159222     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2007.07.011     Document Type: Article

References (21)

1. Anderson J.A., and Saenko E.L. Heparin resistance. Br J Anaesth 88 (2002) 467-469
2. Cohen J.A. Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass. Anesthesiology 60 (1984) 121-124
3. Culliford A.T., Gitel S.N., Starr N., et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 193 (1981) 105-111
4. Despotis G.J., Summerfield A.L., Joist J.H., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 (1994) 1076-1082
5. Brister S.J., Ofosu F.A., and Buchanan M.R. Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?. Thromb Haemost 70 (1993) 259-262
6. Chung J.H., Gikakis N., Rao A.K., et al. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 93 (1996) 2014-2018
7. Boisclair M.D., Lane D.A., Philippou H., et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82 (1993) 3350-3357
8. Codispoti M., Ludlam C.A., Simpson D., et al. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 71 (2001) 922-927
9. Despotis G.J., Joist J.H., Hogue Jr. C.W., et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 110 (1995) 46-54
10. Despotis G.J., Joist J.H., Hogue Jr. C.W., et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 76 (1996) 902-908
11. Koster A., Fischer T., Praus M., et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 97 (2002) 837-841
12. Shirota K., Watanabe T., Takagi Y., et al. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. Artif Organs 24 (2000) 49-56
13. Machin D., and Devine P. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol 37 (2005) 265-271
14. Bull B.S., Huse W.M., Brauer F.S., et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69 (1975) 685-689
15. Philippou H., Adami A., Davidson S.J., et al. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 84 (2000) 124-128
16. Tabuchi N., de Haan J., Boonstra P.W., et al. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 106 (1993) 828-833
17. Slaughter T.F., Mark J.B., El-Moalem H., et al. Hemostatic effects of antithrombin III supplementation during cardiac surgery: Results of a prospective randomized investigation. Blood Coagul Fibrinolysis 12 (2001) 25-31
18. Hogg P.J., and Jackson C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci U S A 86 (1989) 3619-3623
19. Despotis G.J., Santoro S.A., Spitznagel E., et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 107 (1994) 271-279
20. Koster A., Despotis G., Gruendel M., et al. The plasma-supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg 95 (2002) 26-30
21. Koster A., Fischer T., Gruendel M., et al. Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 17 (2003) 171-175